WO2008088149A1

WO2008088149A1 - Corynebacterium glutamicum variety producing l-arginine and method for fabricating the same

Info

Publication number: WO2008088149A1
Application number: PCT/KR2008/000205
Authority: WO
Inventors: Hye Won Kim; Hyejin Choi; Ji-Hye Lee; Soo Youn Hwang; Sun Young Lee
Original assignee: CJ CheilJedang Corp
Current assignee: CJ CheilJedang Corp
Priority date: 2007-01-18
Filing date: 2008-01-11
Publication date: 2008-07-24
Anticipated expiration: 2009-07-18
Also published as: KR100830290B1

Abstract

The present invention relates to an L-arginine producing mutant strain, and a method for fabricating the same. In particular, the present invention relates to a polynucleotide comprising an argF2 gene(Ncg 10990) that is a putative gene of ornithine carbamoyltransferase involved in arginine biosynthesis of Corynebacterium glutamicum, a polypeptide encoded by the polynucleotide, a recombinant vector comprising the polynucleotide, a transformant capable of producing L-arginine in a high yield, which is prepared by introducing the recombinant vector into an L-arginine producing host microorganism, and a method for producing L-arginine by culturing the transformant. The transformant of the present invention overexpresses the argF2 gene to produce L-arginine in a high yield, thereby being used in medicinal and pharmaceutical industries.

Description

CORYNEBACTERIUM GLUTAMICUM VARIETY

PRODUCING L-ARGININE AND METHOD FOR

FABRICATING THE SAME

Technical Field

[1] The present invention relates to an L-arginine producing mutant strain, which produces L-arginine in a high yield to be used in medicinal and pharmaceutical industries, and a method for fabricating the same. In particular, the present invention relates to a polynucleotide comprising an argF2 gene(Ncg 10990) which is a putative gene of ornithine carbamoyltransferase involved in arginine biosynthesis of Corynebacterium glutamicum, a polypeptide encoded by the polynucleotide, a recombinant vector comprising the polynucleotide, a transformant capable of producing L-arginine in a high yield, which is prepared by introducing the recombinant vector into an L-arginine producing host microorganism to overexpress the argF2 gene, and a method for producing L-arginine by culturing the transformant.

[2]

Background Art

[3] L-arginine is a free-form amino acid found in plant seeds or garlic. L-arginine has been widely used as an efficient additive in medicaments, food, or the like. L-arginine is useful as a drug for improving the hepatic function and brain function and treating male sterility, and as an ingredient of multiple amino acid supplements. Also, L- arginine has been used as a food additive in fish cakes and health beverages, and has recently gained interest as a salt substitute for hypertension patients.

[4] Conventional methods for L-arginine production by biological fermentation are based on the production of L-arginine directly from carbon and nitrogen sources. For example, L-arginine can be produced using a mutant strain derived from a glutamic acid-producing microorganism belonging to the genus Brevibacterium or Corynebacterium (Japanese Unexamined Patent Publication Nos. Sho57- 163487, ShoβO-83593 and Sho62-265988), or using an amino acid-producing microorganism, of which growth properties are improved through cell fusion (Japanese Unexamined Patent Publication No. Sho59-158185). Recently, it has been reported that L-arginine can be produced using a recombinant strain, of which an argR gene that participates in regulation of arginine biosynthesis is inactivated (US Patent Application No. 2002/0045223A1) and using a method for over-expressing an argF geneof arginine operon (Korean Patent Application No. 10-2004-107215).

[5] In microorganisms, biosynthesis of L-arginine proceeds in eight enzymatic steps starting from the precursor L-glutamate and follows two different pathways, the linear pathway or the cyclic pathway.

[6] In microorganisms belonging to the genus Corynebacterium, L-arginine is synthesized through the cyclic pathway from L-glutamate via N-acetylglutamate, N- acetylglutamyl phosphate, N-acetylglutamate semialdehyde, N-acetylornithine, ornithine, citrulline and argininosuccinate. These intermediates are synthesized through consecutive reactions catalyzed by enzymes such as glutamate N-acetyltransferase, N- acetylglutamate kinase, acetylglutamate semialdehyde dehydrogenase, acetylornithine aminotransferase, ornithine cabomoyltransferase, arginosuccinate synthase, and arginosuccinate lyase. These enzymes are encoded by argj, argB, argC, argD, argF, argG and argH genes, respectively.

[7] In order to produce L-arginine in a high yield, the present inventors have conducted studies on the enzymes involved in L-arginine biosynthesis for a long period time. They found that in the intermediate step of arginine biosynthesis, the enzymatic reaction involved in the conversion of ornithine to citrulline is amplified to increase L- arginine flux, thereby improving the productivity of L-arginine. Accordingly, the present inventors confirmed that the argF geneencodingornithine carbamoyltransferase was amplified to increase the productivity of L-arginine (Korean Patent Application No. 10-2006-065989), and they have continued to develop strains capable of producing L-arginine in a high yield.

[8] It has been known that in Corynebacterium glutamicum, an argCJBDF gene involved in arginine biosynthesis exists as an operon, and is regulated by feedback- inhibition due to arginine (Vehary Sakanyan, et al, Microbiology, 142:9-108, 1996). Thus, there is a limit in producing L-arginine in a high yield.

[9]

Disclosure of Invention Technical Problem

[10] Accordingly, the present inventors have made an effort to develop strains capable of producing L-arginine in higher yield. They found that a microorganism transformed with an argF2 gene, which is a putative gene having the same function as an argF gene encoding ornithine carbamoyltransferase, overexpresses the argF2 gene and produces L-arginine in higher yield than a parent strain, thereby completing the present invention.

[H]

Technical Solution

[12] It is an object of the present invention to provide a polypeptide encoded by an argF2 gene(Ncgl0990) that is a putative gene of ornithine carbamoyltransferase involved in arginine biosynthesis of Corynebacterium glutamicum.

[13] It is another object of the present invention to provide a recombinant vector comprising a base sequence encoding the polypeptide.

[14] It is still another object of the present invention to provide a transformant capable of producing L-arginine in a high yield, which is prepared by introducing the recombinant vector.

[15] It is still another object of the present invention to provide a method for producing

L-arginine by culturing the transformant.

[16]

Brief Description of the Drawings

[17] Fig. 1 illustrates the construction of a recombinant plasmid pHC131T-αrgF2, comprising an argF2 gene, CJl promoter and rrnB B terminator.

[18]

Best Mode for Carrying Out the Invention

[19] In one embodiment, the present invention provides a polypeptide encoded by an argF2 gene(Ncgl0990) which is a putative gene of ornithine carbamoyltransferase involved in arginine biosynthesis of Corynebacterium glutamicum. Preferably, an amino acid sequence of the polypeptide may be represented by SEQ ID NO. 1.

[20] It has been known that according to sequencing analysis, the argF2 gene(Ncg 10990) which is a putative gene of ornithine carbamoyltransferase involved in arginine biosynthesis of Corynebacterium glutamicum ATCC 13032 has 32% homology with the argF gene of Magnetospirillum magnetotacticum, and has acarbamoyl-P binding domain at N-terminal region (KEGG Database), however, function of the protein encoded by the argF2 has not been clearly identified. The sequence homology between argF and argF2 genes is low. The motif search in KEGG Database, however, results in that the argF2 gene has pf:OTCace_N (Aspartate/ornithine carbamoyltransferase, carbamoyl-P binding domain) and pf:OTCace (Aspartate/ornithine carbamoyltransferase, Asp/Orn binding domain), and the argF genealso has the same motif. Both of the argF and argF2 genes have the carbamoyl-P binding domain and Asp/Orn binding domain. Therefore, it is inferred that the protein encoded by the argF2 gene has similar function to ornithine carbamoyltransferase that is encoded by the argF gene and required for arginine biosynthesis (KEGG Database search result). In a specific embodiment of the present invention, it can be seen that the L-arginine producing strain transformed with a recombinant vector comprising the argF2 gene produces L- arginine in higher yield than a parent strain.

[21] In another embodiment of the present invention, the present invention provides a polynucleotide encoding an amino acid sequence of SEQ ID NO. 1. Preferably, the base sequence of the polynucleotide may be represented by SEQ ID NO. 2. Further, the present invention provides a polynucleotide having 70% or more homology with the base sequence of SEQ ID NO. 2, preferably 90% or more homology with the base sequence of SEQ ID NO. 2.

[22] In still another embodiment of the present invention, the present invention provides a recombinant vector comprising the polynucleotide. Preferably, the recombinant vector may comprise the polynucleotide represented by SEQ ID NO. 2, and may be a recombinant vector pHC131T-αrgF2 prepared according to a specific embodiment of the present invention (Fig. 1).

[23] The recombinant vector may be easily fabricated by those skilled in the art according to any known method using DNA recombination technique. For example, in an embodiment of the present invention, the genomic DNA is isolated from the L- arginine producing strain, and PCR is performed using the isolated genomic DNA as a template to amplify the ORF region of argF2 gene. To fabricate a recombinant vector for the argF2 gene overexpression, CJl promoter (Korean Patent No. 10-0620092) and rrnB B terminator regions are amplified using pECCGl 17-CJl and E.coli K-12 as a template, respectively. The CJl promoter that is known as the upstream region of Corynebacterium ammoniagenes Hsp60 and strongly expressed in Corynebacterium glutamicum, and commercially available rrnBlB2 terminator are used as a promoter and terminator, respectively. In this connection, the base sequence of argF2 geneis analyzed by a conventional sequencing method. The promoter region, terminator region and argF2 gene are cloned into a suitable plasmid or other cloning vectors, and transformed into suitable competent cells to fabricate a recombinant vector (Fig. 1).

[24] In the fabrication of the recombinant vector, any vector expressed in prokaryotic or eukaryotic cells may be used as a cloning vector, and in a specific embodiment of the present invention, a plasmid pECCGl 17 (Han J.K., et al, Biotechnology letters, 13(10):721-726, 1991 or Korean Patent Publication No. 92-7401) is used. Further, the L-arginine producing strain encompasses all microorganisms capable of producing L- arginine, including prokaryotic or eukaryotic cells, preferably Escherichia coli, coryneform bacteria, and Bacillus species capable of producing L-arginine, and more preferably Corynebacterium glutamicum capable of producing L-arginine.

[25] In still another embodiment, the present invention provides a microorganism that is transformed by introducing the recombinant vector comprising the argF2 gene into a host microorganism.

[26] Specifically, the host microorganism may be any microorganism capable of producing L-arginine, including prokaryotic or eukaryotic cells. The preferred Examples thereof include any one selected from the group consisting of thespecies Escherichia, Aerobacter, Schizosaccharomyces, Pichia, Kluyveromyces, Candida, Hansenula, Debaryomyces, Zygosaccharomyces, Mucor, Torulopsis, Methylobacter, Salmonella, Bacillus, Streptomyces, Pseudomonas, Brevibacterium, Magneto spirillum and Corynebacterium, more preferably microorganisms belonging to the genus Corynebactrium, whichhave a resistance to L-arginine analogues and produce L- arginine, and most preferably Corynebacterium glutamicum ATCC21831. Examples of the L-arginine analogues include an alpha-amino acid canavanine found in Canavalia ensiformis and arginine hydroxamate.

[27] In a specific embodiment of the present invention, the recombinant vector pHC131T-αrgF2 is introduced into Corynebacterium glutamicum ATCC21831, which has a resistance to L-arginine analogues and produces L-arginine, so as to prepare a transformed microorganism "CA06-0011". The transformed microorganism CA06-0011 was deposited at the Korean Culture Center of Microorganisms (hereinafter, abbreviated to "KCCM") on December 13, 2006 under accession number KCCM10819P.

[28] The transformed microorganism can be easily prepared by those skilled in the art according to any known method. The term "transformation" as used herein means introducing DNA into a host cell so that DNA is replicable, either as an extra- chromosomal element or by chromosomal integration, that is, artificial genetic alteration by introducing a foreign DNA into a host cell. Examples thereof include a CaCl precipitation, a Hanahan method that is an improved CaCl method by using DMSO (dimethyl sulfoxide) as a reducing material, electroporation, calcium phosphate precipitation, protoplast fusion, agitation using silicone carbide fiber, Agrobacterium- mediated transformation, PEG-, dextran sulfate-, and lipofectamine-mediated transformation. In one embodiment of the present invention, the recombinant vector pHC131T-αrgF2 were introduced into a host cell by electroporation to prepare a transformant, and a strain harboring the recombinant vector was selected using its antibiotic resistance.

[29] To increase the L-arginine productivity of the transformant prepared according to the present invention, the argF2 gene present in the chromosome of the transformant may be additionally subjected to expression or deletion by a conventional recombinant technique. It is known in the related art that its base sequence can be analyzed by a sequencing method using fluorescence.

[30] In the biosynthetic pathway of L-arginine, ornithine is an intermediate of the metabolic pathway of arginine and is an important material in nitrogen metabolism along with the urea cycle. The CA06-0011 strain transformed by the method of the present invention is a transformant overexpressing the argF2 gene, prepared by the following method. The argF2 gene encoding a putative protein having a function of ornithine carbamoyltransferase, which is obtained by PCR from the chromosome of the L-arginine producing strain, Corynebacterium glutamicum ATCC 13032, is inserted into a vector, and introduced into the L-arginine producing strain, Corynebacterium glutamicum ATCC21831. It was found that the transformed CA06-0011 strain according to the present invention overexpresses the argF2 gene to produce L-arginine in a high yield.

[31] Accordingly, in another embodiment, the present invention provides a method for producing L-arginine, comprising the step of culturing the transformant, preferably transformant represented by accession number KCCM 10819P.

[32] In the production method of L-arginine of the present invention, the cultivation of the transformed microorganism overexpressing L-arginine may be conducted in suitable media and under culture conditions known in the art. The culturing procedures can be readily adjusted by those skilled in the art according to the selected strain. Examples of the culturing procedures include batch type, continuous type and fed- batch type manners, but are not limited thereto. Various culturing procedures are disclosed in literature, for example, "Biochemical Engineering" (James M. Lee, Prentice-Hall International Editions, pp 138-176, 1991).

[33] During cultivation, ammonium hydroxide, potassium hydroxide, ammonia, phosphoric acid, and sulfuric acid may be properly added to adjust the pH of the cultures. Defoaming agents such as fatty acid polyglycol ester may be properly added to reduce the formation of foams in cultures. Further, to maintain the cultures in aerobic states, oxygen or oxygen-containing gas (e.g., air) may be injected into the cultures. The cultures are maintained at 20 to 45⁰C and preferably at 25 to 4O⁰C. The cultivation may be continued until a desired amount of L-arginine is obtained, and preferably for 10 to 160 hrs. The isolation of L-arginine from the culture broth may be performed by the conventional method known in the art. Examples thereof may include centrifugation, filtration, ion-exchange chromatography, and crystallization. For example, the cultures may be subjected to low-speed centrifugation to remove the biomass, and the supernatant may be separated by ion-exchange chromatography.

[34]

Mode for the Invention

[35] Hereinafter, the present invention will be described in more detail with reference to

Examples. However, these Examples are for the illustrative purpose only, and the invention is not intended to be limited by these Examples.

[36]

[37] Example 1. Preparation of arsF2 gene . CJl promoter and rrnB B_ terminator

[38] To construct a recombinant vector pHC131T-αrgF2 comprising an argF2 gene, CJl promoter, and rrnB B terminator, a DNA fragment (825 bp) including Open Reading Frame (hereinafter, abbreviated to "ORF") of arg F '2 genewas obtained from the genomic DNA (gDNA) of L-arginine producing strain ATCC 13032, and PCR was performed using pECCG117-C.ll (Korean Patent Application No. 10-2004-107215) and the genome of E.coli K- 12 W3110 as a template to obtain the CJl promoter (300 bp) and the rrnB B terminator (411 bp), respectively.

[39]

[40] Example 1-1. Amplification of DNA fragment including ORF of arsF2 gene

[41] The genomic DNA (gDNA) was extracted from Corynebacterium glutamicum

ATCC 13032 using a Masterpure Gram positive DNA purification kit (Epicentre, hereinafter the same). In order to amplify the DNA fragment (825 bp) including ORF of argF2 gene, polymerase chain reaction (hereinafter, abbreviated to "PCR") was performed using the gDNA as a template and a PTC-200 Peltier Thermal Cycler (MJ Research, USA, hereinafter the same). At this time, primers used in the amplification of the ORF region of argF2 gene were as follows: SEQ ID NO. 5; 5'-acgcgatatcatggccagaaaacatctgc-3' and SEQ ID NO. 6;

5'-catccgccaaaacagggatccgaaaaccgctacgcattgat-3'. PCR conditions included 24 cycles of denaturation at 94⁰C for 30 sec, annealing at 55⁰C for 30 sec and extension at 68⁰C for 1 min. The PCR product was subjected to electrophoresis on a 0.8% agarose gel, and then a band of 0.8 kb was eluted from the gel.

[42]

[43] Example 1-2. Amplification of CJl promoter

[44] To amplify the CJl promoter, PCR was performed using pECCGl 17-CJl (Korean

Patent Application No. 10-2004-107215) as a template and a PTC-200 Peltier Thermal Cycler. At this time, primers used in the amplification of CJl promoter were as follows: SEQ ID NO. 3; 5'-cgggtaccaccgcgggcttattccattacat-3' and SEQ ID NO. 4; 5'-acgcgatatcttaatctcctagattgggtttc-3'. PCR conditions included 24 cycles of denaturation at 94⁰C for 30 sec, annealing at 55⁰C for 30 sec and extension at 68⁰C for 30 sec. The PCR product was subjected to electrophoresis on a 1.0% agarose gel, and then a band of 0.3 kb was eluted from the gel.

[45]

[46] Example 1-3. Amplification of rrnB B_ terminator

[47] The genomic DNA (gDNA) was extracted from E.coli K-12 W3110 using a Qiagen

Genomic DNA kit (QIAGEN, Germany). To amplify the rrnB B terminator, PCR was performed using the gDNA as a template and a PTC-200 Peltier Thermal Cycler. At this time, primers used in the amplification of rrnB B terminator were as follows: SEQ ID NO. 7; 5'-gctctagagctgttttggcggatgaga-3' and SEQ ID NO. 8; 5'-ataagaatgcggccgccgcaaaaaggccatccgtcag-3'. PCR conditions are the same as in the amplification of CJl promoter of Example 1-2. The PCR product was subjected to electrophoresis on a 1.0% agarose gel, and then a band of 411 bp was eluted from the gel.

[48]

[49] Example 2. Construction of recombinant plasmid

[50] Example 2-1. Construction of recombinant plasmid pHC131T

[51] A plasmid pECCG-117 (Han J.K., et al, Biotechnology letters, 13(10):721-726,

1991 or Korean Patent Publication No. 92-7401), which is an E. coli/C. glutamicum shuttle vector, was treated with restriction enzymes, EcoRV and Kpnl, and then subjected to electrophoresis on a 0.8% agarose gel to elute a band of about 5.9 Kb. Further, the CJl promoter prepared in Example 1-2 was treated with restriction enzymes, Kpnl and EcoRV, and then isolated using a Quiaquick PCR purification kit (Qiagen, hereinafter the same).

[52] Two DNA fragments were ligated using a Quick ligation kit (NEB, hereinafter the same) to prepare a recombinant plasmid pECCGl 17-CJl. The recombinant plasmid pECCGl 17-CJl was treated with restriction enzymes, Xbal and Notl, and then subjected to electrophoresis on a 1% agarose gel to elute a band of about 6.2 Kb.

[53] The prepared pECCGl 17-CJl and the rrnB B terminator prepared in Example 1-3 were ligated using a Quick ligation kit to obtain a recombinant plasmid pECCGl 17-CJl-rrnB B (about 6.6 Kb), which was designated as "pHC131T" in the present invention.

[54] The prepared pHC131T plasmid was treated with EcoRV and BamHI, and then subjected to electrophoresis on a 1% agarose gel to elute a band of about 6.6 Kb from the gel.

[55]

[56] Example 2-2. Construction of plasmid pHC131T-argF2

[57] The PCR product of argF2 gene prepared in Example 1-1 was treated with restriction enzymes, EcoRV and BamHI, and then isolated using a Quiaquick PCR purification kit. The resultant was ligated with pHC131T prepared in Example 2-1 using a Quick ligation kit, so as to construct a recombinant plasmid of about 7.4 Kb (Fig. 1), which was designated as "pHC131T-αrgF2"in the present invention.

[58]

[59] Example 3. Sequencing analysis of argF2 gene

[60] To analyze the base sequence ofpHC131T-αrgF2 prepared in Example 2-2, PCR was performed using 0.1 ug DNA of pHC131T-αrgF2 as a template with 2 mM of a pair of primers of SEQ ID NOs. 3 and 8 and 1 D of a BigDye Terminator Cycle Sequencing v2.0 Ready Reaction (PE Biosystems). PCR conditions included 24 cycles of denaturation at 95⁰C for 30 sec, annealing at 55⁰C for 30 sec and extension at 72⁰C for 1 min and 30 sec, followed by quenching at 4⁰C to terminate the reaction. The PCR product was subjected to electrophoresis on a 0.8% agarose gel, and then a DNA fragment of 1.5 kb was eluted from the gel.

[61] This DNA fragment was subjected to sequencing analysis using the primer of SEQ

ID NO. 5 on an ABI PRISM 3100 Genetic Analyzer™ (Applied Biosystems). As a result, it was confirmed that the argF2 gene has 32% homology with the argF gene of Magnetospirillum magnetotacticum, and even though the sequence homology between argF and argF2 genes is low, the argF2 has pf:OTCace_N (Aspartate/ornithine car- bamoyltransferase, carbamoyl-P binding domain) and pf:OTCace (Aspartate/ornithine carbamoyltransferase, Asp/Orn binding domain), and the argF genealso has the same motif. Both of the argF and argF2 genes have the carbamoyl-P binding domain and Asp/Orn binding domain. Therefore, it is inferred that the protein encoded by the argF2 gene has similar function to ornithine carbamoyltransferase that is encoded by the argF gene and required for arginine biosynthesis (KEGG Database search result). An amino acid sequence encoded by the argF2 gene of the present invention and a base sequence thereof are shown in SEQ ID NOs. 1 and 2, respectively.

[62]

[63] Example 4. Preparation of transformant

[64] The recombinant plasmid pHC13 \T-argF2 prepared in Example 2-2 was introduced into an L-arginine producing strain ATCC21831 by electroporation to prepare transformants overexpressing the argF2 gene, which were designated as CA06-0011. The transformed microorganism CA06-0011 was deposited at the Korean Culture Center of Microorganisms (hereinafter, abbreviated to "KCCM") on December 13, 2006 under accession number KCCM10819P.

[65] The ATCC21831 strain and transformant CA06-0011 were smeared on solid media

#3 containing 25 mg/L of Kanamycin (Nutrient medium, hereinafter abbreviated to "#3", composition: 3 g/L of Beef extract, 5 g/L of peptone, 10 g/L of sodium chloride, hereinafter the same), and cultured at 3O⁰C for 16 hrs. The selected colonies were subjected to a flask titer test as the following Example 5. As a result, it was found that the αrgF2-overexpressing transformant according to the present invention produced L- arginine in a high yield.

[66]

[67] Example 5. Comparison of arginine production titer in Erlenmeyer flask

[68] The transformant CA06-0011 prepared in Example 4 and L-arginine producing strain ATCC21831 were smeared on solid media #3 containing 25 mg/L of Kanamycin, and cultured at 3O⁰C for 16 hrs to select 10 single colonies from each strain. The selected colonies were cultured in L-arginine seed media given in Table 1, and then evaluated for L-arginine productivity in an Erlenmeyer flask using titer media given in Table 1. The mean values of the L-arginine productivity were calculated and compared.

[69] Table 1

[70] [71] The selected colonies were inoculated in the seed media and cultured in an incubator at 3O⁰C for 16 hrs. 1 ml of the seed culture was inoculated in 24 ml of the titer media, and culturing was carried out at 3O⁰C and 220 rpm for 72 hrs. The results of L-arginine production titer test for ATCC21831 and transformant are given in Table 2.

[72] As shown in Table 2, the arginine producing strain Corynebacterium glutamicum ATCC 21831 exhibited L-arginine productivity of 4.4 g/L. Meanwhile, the argF2 - overexpressing recombinant strain CA06-0011 of the present invention exhibited L- arginine productivity of 5.2 g/L. It can be seen that the productivity of the recombinant strain CA06-0011 was increased by 0.6 g/L (18.2%), as compared to the parent strain.

[73] Table 2

[74]

[75] It will be apparent to those skilled in the art that various modifications and changes may be made without departing from the scope and spirit of the invention. Therefore, it should be understood that the above Examples and Experimental Examples are not limitative, but illustrative in all aspects. The scope of the invention is defined by the appended claims rather than by the description preceding them, and therefore all changes and modifications that fall within meets and bounds of the claims, or equivalents of such meets and bounds are therefore intended to be embraced by the claims.

[76]

Industrial Applicability

[77] The present invention provides a polynucleotide comprising an argF2 gene(

Ncgl0990) that is a putative gene of ornithine carbamoyltransferase involved in arginine biosynthesis of Corynebacterium glutamicum, a polypeptide encoded by the polynucleotide, a recombinant vector comprising the polynucleotide, a transformant prepared by introducing the recombinant vector into an L-arginine producing host microorganism, and a method for producing L-arginine by culturing the transformant. The transformant of the present invention overexpresses the argF2 gene to produce L- arginine in a high yield, thereby being used in medicinal and pharmaceutical industries.

[78]

[79]

BUDAPEST TREATY ON THE INTERNATIONAL

RECOGNITION OF THE DEPOSIT OF MICROORGANISMS

FOR THE PURPOSES OF PATENT PROCEDURE

INTERNATIONAL FORM

To. CJ Corp.

500 5-GA NAMDAEMUN-RO RECEIPT IN THE CASE OF AN ORIGINAL CHUNG-KU, SEOUL issued pursuant to HuIe 7.1 by the INTERNATIONAL DEPOSITARY AUTHORITY REPUBLIC OF KOREA identified at the bottom of this page

by the AUTHORITY:

DESIGNATION by:

identified under I above, which was

of person(s) having the power

status of authority was acquired; where a deposit made outside the Budapest Treaty after the acquisition of the status of international depositary authority is converted into a deposit under the Budapest Treaty, such date is the date on which the microorganism was received by the international depositary authouity. Form BP/4 Sole page

— gr≡Sπi-ϊΪΞ-≤g'-iei •^•;

[80]

Claims

[1] An L-arginine producing microorganism that is transformed with a recombinant vector comprising a polynucleotide encoding an argF2 polypeptide.

[2] The L-arginine producing microorganism according to claim 1, wherein the argF2 polypeptide has an amino acid sequence represented by SEQ ID NO. 1.

[3] The L-arginine producing microorganism according to claim 1, wherein the polynucleotide is represented by SEQ ID NO. 2.

[4] The L-arginine producing microorganism according to claim 1, wherein the microorganism belongs to the genus Corynebacterium.

[5] The L-arginine producing microorganism according to claim 1, wherein the microorganism is identified by accession number KCCM 10819P.

[6] A method for producing L-arginine, comprising the step of culturing the microorganism of any one of claims 1 to 5.